Groups treated with RBO (0.2–0.4 mL/rat) for two weeks post-induction of liver fibrosis showed a significant (p≤0.05) reduction of liver hydroxyproline (3707.3±265.13 and 3137.9±258.49 ng/mL), collagen I (38.4±2.19 and 36.4±2.99 ng/mL) and CTGF (1666.6±57.80 and 1564.6±55.34 pg/mL) as compared to control positive group and showing % of reduction in hydroxyproline (23.15% and 34.96%), collagen I (40.83% and 43.91%) and CTGF (18.24% and 23.24%). The gene discussed is CCN2; the disease is Hepatic fibrosis.